Diplomat to Participate in Upcoming Investor Conference
FLINT, Mich. – June 1, 2015 – Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation’s largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman & CEO, and Sean Whelan, CFO, will present at two upcoming investor conferences.
Mr. Hagerman and Mr. Whelan are scheduled to present at the William Blair 35th Annual Growth Stock Conference in Chicago on Wednesday, June 10, 2015 at 8:00 AM CT.
Mr. Hagerman and Mr. Whelan are also scheduled to take part in an analyst-led fireside chat at the Leerink Partners Healthcare Services & HCIT Roundtable in New York on Thursday, June 18, 2015 at 10:30 AM ET.
Live audio-only webcasts of the William Blair presentation and related materials will be available on the investor relations section of the Company’s website at ir.diplomat.is. The archived webcast and presentation materials will also be available for 90 days at the same URL.
Forward Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include the Company’s expectations regarding future tax benefits, and the financial and operational performance of the combined entities. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: delays or difficulties in integrating the combined businesses; general economic conditions in the regions and industries in which the parties operate; and the ability to achieve cost savings and operating synergies and the timing thereof. The foregoing transaction risks should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues — always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Bob East, Westwicke Partners
443.213.0500 | firstname.lastname@example.org
Jenny Cretu, Diplomat
810.768.9370 | email@example.com